Quick Answer
For United States medical-device manufacturing surplus, prepare a buyback request only after identifying which unused electronic components are authorised for transfer. Keep ordinary excess inventory separate from quality holds, recalled finished devices and material under investigation. A clear list of full manufacturer numbers, quantities and release status lets a prospective buyer assess the proposed lot without confusing a commercial inventory reduction with a regulatory corrective action.
This guide concerns component inventory left after a production change, cancelled build or excess procurement. It does not offer a route for bypassing a manufacturer's quality decision. A component purchased for a medical-device programme is not automatically medical grade, and its resale does not establish suitability for another medical application. Preserve the information needed to describe the component honestly while the responsible organisation determines what may leave its control.
Inventory We Buy: Assessment Scope
The review list may include unused amplifiers, converters, interface ICs, power devices, connectors and other identified production components. List each by its original manufacturer number rather than only a device-programme stock code. The original intended use can provide context, but it does not replace electrical identity or documentation of condition.
FDA's device guidance distinguishes recalls, market withdrawals and stock recovery. Those terms have specific meanings; do not use them casually as synonyms for selling excess components. Where a quality or corrective-action issue exists, let the responsible quality and regulatory team determine the permitted disposition before any commercial transfer is proposed. A buyer's interest does not resolve that question.
- Separate material released for disposition from quarantine, nonconforming lots and components connected to an unresolved investigation.
- Distinguish unused purchased components from reclaimed parts, service returns and assemblies removed from clinical equipment.
- Preserve lot-level references needed by the seller's quality system while excluding patient information and unnecessary confidential records.
How Buyback Works
Start with an internal disposition decision and a list of the material it covers. Record the decision owner, date and any limitations. The buyer-facing file can then describe the permitted inventory without exposing the manufacturer's complete device history or proprietary design documentation.
Keep changes controlled throughout the process. If a component lot is placed on hold after an initial enquiry, update the proposed sale list immediately and retain the reason in the seller's internal record. If a count changes, issue a revised manifest rather than silently editing a spreadsheet already used for an offer. These practices make the commercial discussion reviewable without pretending that an enquiry itself constitutes a quality release.
- Reconcile the released part numbers and lots with the physical containers and quantities proposed for assessment.
- Prepare packaging photographs and a list of the available source records, clearly distinguishing missing records from records intentionally withheld.
- Agree the scope of further review, any sampling arrangements and the final line items before the seller releases material.
Valuation and Timing
A prospective buyer assesses the actual component identity, quantity, condition, documentation and potential demand. The fact that a component was bought for a medical programme does not by itself justify a premium or prove a special grade. Evidence should identify manufacturer specifications and the offered lot, rather than relying on the reputation of the original end product.
Timing may depend on internal release and record preparation more than on the physical size of the lot. State the seller's decision deadline and whether quality review is complete. A conditional proposal should remain visibly conditional until the relevant people have resolved its conditions. Avoid promising a dispatch date based only on an initial inventory spreadsheet.
When comparing offers, identify whether they cover the same approved lines and assume the same documents. Agree inspection, quantity reconciliation, payment and transfer arrangements in writing. This guide supplies no recovery percentage, guaranteed acceptance or standard payment term. Those details belong to the specific transaction and should reflect what both parties can actually verify and perform.
Preparing Your Inventory
Prepare a clean assessment file containing the original manufacturer, exact part number, quantity, packaging, lot or date code, condition and disposition status. Add an internal reference linking each line back to the seller's controlled records. Use descriptions such as unopened reel or opened tray only when supported by observation; do not infer storage history from a neat outer box.
Explain any repackaging or partial use. Keep original labels and disclose where quantities have been estimated. If material has been programmed or configured for a particular device, identify the limitation and determine whether the seller is authorised to transfer it. Do not share proprietary firmware, keys or clinical information merely to make a component offer appear more complete.
At the end of review, reconcile accepted, excluded and unresolved lines. Keep the final manifest and the seller's release evidence together. The buyer should receive the agreed component information, while the seller retains its own required quality records. This creates a clear boundary between an authorised sale of documented surplus and unresolved material that still needs an internal quality, regulatory or waste-management decision.
FAQ
Are unused parts from a medical factory automatically medical grade?
No. Identify the actual manufacturer grade and specifications. The original procurement programme does not create a new component certification, and any future medical use still requires qualification of the receiving organisation's board and finished device.
Can a quality-hold lot be offered as ordinary excess?
Do not describe it that way while its disposition is unresolved. The responsible quality and regulatory personnel should determine the permitted action. A commercial enquiry, attractive offer or unused appearance does not remove the underlying hold.
What documentation should be shared for initial review?
Start with exact part numbers, quantities, condition, permitted disposition and available provenance. Keep patient data, credentials and unnecessary confidential design records out of the assessment package. More detailed evidence can be scoped to a legitimate, agreed review need.
Request a review of your excess inventory list
Sources
- FDA: Recalls, Corrections and Removals for Devices (checked 2026-10-02)